NKTR insider trading
NasdaqCM HealthcareNEKTAR THERAPEUTICS: insider trade history from SEC Form 4 filings.
About NEKTAR THERAPEUTICS
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Company website: www.nektar.com
NKTR insider activity at a glance
FilingIQ tracks 820 insider transactions for NKTR in filings since Jan 15, 2015. The most recent transaction is dated Sep 23, 2026.
Across the full history, 6 open-market purchases
and 432 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NKTR insider trades is 57.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NKTR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for NKTR?
- FilingIQ tracks 820 Form 4 insider transactions for NKTR (NEKTAR THERAPEUTICS), covering filings from Jan 15, 2015 onwards. 7 of those are dated within the last 90 days.
- Are NKTR insiders net buyers or net sellers?
- Across the full Form 4 history for NKTR, 6 transactions (1%) were open-market purchases and 432 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NKTR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is NKTR in?
- NEKTAR THERAPEUTICS (NKTR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.03B.
Methodology & sources
Every NKTR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.